NASDAQ:IONS Ionis Pharmaceuticals (IONS) Stock Price, News & Analysis → Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad) Free IONS Stock Alerts $43.35 -1.31 (-2.93%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$43.32▼$44.9550-Day Range$42.03▼$52.0152-Week Range$34.32▼$54.44Volume2.00 million shsAverage Volume1.21 million shsMarket Capitalization$6.32 billionP/E RatioN/ADividend YieldN/APrice Target$55.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Ionis Pharmaceuticals alerts: Email Address Ionis Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside28.4% Upside$55.67 Price TargetShort InterestBearish7.22% of Float Sold ShortDividend StrengthN/ASustainability-3.58Upright™ Environmental ScoreNews Sentiment0.51Based on 6 Articles This WeekInsider TradingSelling Shares$5.15 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($3.92) to ($3.50) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.26 out of 5 starsMedical Sector146th out of 938 stocksPharmaceutical Preparations Industry56th out of 417 stocks 4.3 Analyst's Opinion Consensus RatingIonis Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 7 buy ratings, 3 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $55.67, Ionis Pharmaceuticals has a forecasted upside of 28.4% from its current price of $43.35.Amount of Analyst CoverageIonis Pharmaceuticals has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted7.22% of the float of Ionis Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverIonis Pharmaceuticals has a short interest ratio ("days to cover") of 8.1.Change versus previous monthShort interest in Ionis Pharmaceuticals has recently increased by 6.15%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldIonis Pharmaceuticals does not currently pay a dividend.Dividend GrowthIonis Pharmaceuticals does not have a long track record of dividend growth. Previous Next 3.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreIonis Pharmaceuticals has received a 27.23% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Neuromuscular disorders medication" product. See details.Environmental SustainabilityThe Environmental Impact score for Ionis Pharmaceuticals is -3.58. Previous Next 2.5 News and Social Media Coverage News SentimentIonis Pharmaceuticals has a news sentiment score of 0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Ionis Pharmaceuticals this week, compared to 5 articles on an average week.Search InterestOnly 12 people have searched for IONS on MarketBeat in the last 30 days. This is a decrease of -14% compared to the previous 30 days.MarketBeat Follows9 people have added Ionis Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 29% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ionis Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,152,226.00 in company stock.Percentage Held by InsidersOnly 2.65% of the stock of Ionis Pharmaceuticals is held by insiders.Percentage Held by Institutions93.86% of the stock of Ionis Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Ionis Pharmaceuticals are expected to grow in the coming year, from ($3.92) to ($3.50) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ionis Pharmaceuticals is -16.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ionis Pharmaceuticals is -16.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIonis Pharmaceuticals has a P/B Ratio of 16.06. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad WealthPress$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…Go here to watch the most recent trading workshop video at no charge. About Ionis Pharmaceuticals Stock (NASDAQ:IONS)Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.Read More IONS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IONS Stock News HeadlinesMarch 8, 2024 | marketbeat.comAre These 5 Undervalued Stocks Ready to Break Out?Albemarle Corp. NYSE: ALB, Ionis Pharmaceuticals Inc. NASDAQ: IONS, Insulet Corp. NASDAQ: PODD, Hess Corp. NYSE: HES and Wynn Resorts Ltd. NASDAQ: WYNN are among undervalued stocks that beat analysts earnings views.March 8, 2024 | marketbeat.comAre These 5 Undervalued Stocks Ready to Break Out? (IONS)Undervalued stocks Albemarle, Ionis, Insulet, Hess and Wynn beat earnings views, offering potential for investors to buy quality companies at discounted prices.March 29, 2024 | Crypto Swap Profits (Ad)Claim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.March 28, 2024 | prnewswire.comIonis to hold olezarsen Phase 3 data webcastMarch 25, 2024 | prnewswire.comPositive olezarsen Phase 3 data in familial chylomicronemia syndrome to be presented at 2024 American College of Cardiology (ACC) annual meetingMarch 22, 2024 | finance.yahoo.comIonis Pharmaceuticals (IONS) Down 2.8% Since Last Earnings Report: Can It Rebound?March 17, 2024 | ca.finance.yahoo.comIONS Oct 2024 50.000 putMarch 16, 2024 | msn.comNASH drug market expected to surpass $48B by 2035March 29, 2024 | Crypto 101 Media (Ad)Altcoin FRENZY Alert…Bitcoin recently crossed the highest price in its 15-year history… Less than 2 years after one of the most vicious crypto market meltdowns we've ever seen! Bitcoin's BOOM also sent shockwaves through the altcoin market, with select coins seeing HUGE moves in a matter of days… Like Fetch.ai, that gained over 350% in just the last 30 days… March 16, 2024 | finance.yahoo.comIONS Apr 2024 75.000 callMarch 14, 2024 | finance.yahoo.comQ4 2023 Agenus Inc Earnings Call and Corporate UpdateMarch 14, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Chemed (CHE), Ionis Pharmaceuticals (IONS) and Arcellx Inc (ACLX)March 14, 2024 | finance.yahoo.comMadrigal wins FDA approval of first drug for MASHMarch 13, 2024 | benzinga.comGenetic Medicines Focused-Ionis Pharmaceuticals' Fatty Liver Candidate Lowers Excess Liver Fat, Midstage Study Data ShowsMarch 13, 2024 | reuters.comIonis Pharma's fatty liver disease drug succeeds in mid-stage trialMarch 13, 2024 | finance.yahoo.comIonis announces positive results from Phase 2 study of ION224, an investigational medicine demonstrating clinical efficacy in the treatment of NASH/MASHMarch 11, 2024 | msn.comCytokinetics drifts lower as CEO touts standalone strategyMarch 6, 2024 | realmoney.thestreet.comIonis Pharmaceuticals price target raised by $7 at Oppenheimer, here's whyMarch 6, 2024 | markets.businessinsider.comTD Cowen Keeps Their Buy Rating on Ionis Pharmaceuticals (IONS)February 29, 2024 | prnewswire.comIonis announces new chief global product strategy officer to lead next phase of commercial growthFebruary 28, 2024 | prnewswire.comIonis to present at upcoming investor conferencesFebruary 24, 2024 | finance.yahoo.comIonis Pharmaceuticals, Inc. (NASDAQ:IONS) Just Released Its Yearly Results And Analysts Are Updating Their EstimatesFebruary 23, 2024 | seekingalpha.comIonis Pharmaceuticals 2023 Earnings Review: Short-Term Pain, Long-Term GainFebruary 23, 2024 | finance.yahoo.comIonis Pharmaceuticals Full Year 2023 Earnings: Beats ExpectationsFebruary 22, 2024 | benzinga.com2IONS : Cracking The Code: Understanding Analyst Reviews For Ionis PharmaceuticalsFebruary 22, 2024 | finance.yahoo.comIonis Pharmaceuticals, Inc.: Ionis Earnings: Maintaining $62 Fair Value Estimate; Wainua a Precursor to Two Independent LaunchesFebruary 22, 2024 | finance.yahoo.comIonis Pharmaceuticals, Inc. (NASDAQ:IONS) Q4 2023 Earnings Call TranscriptSee More Headlines Receive IONS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ionis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/21/2024Today3/28/2024Next Earnings (Estimated)5/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:IONS CUSIP46433010 CIK874015 Webwww.ionispharma.com Phone(760) 931-9200Fax760-603-2700Employees927Year FoundedN/APrice Target and Rating Average Stock Price Target$55.67 High Stock Price Target$72.00 Low Stock Price Target$28.00 Potential Upside/Downside+28.4%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage12 Analysts Profitability EPS (Most Recent Fiscal Year)($2.56) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-366,290,000.00 Net Margins-46.32% Pretax Margin-42.40% Return on Equity-90.29% Return on Assets-12.39% Debt Debt-to-Equity Ratio3.18 Current Ratio5.90 Quick Ratio5.83 Sales & Book Value Annual Sales$788 million Price / Sales8.02 Cash FlowN/A Price / Cash FlowN/A Book Value$2.70 per share Price / Book16.06Miscellaneous Outstanding Shares145,750,000Free Float141,890,000Market Cap$6.32 billion OptionableOptionable Beta0.40 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Brett P. Monia Ph.D. (Age 63)Founder, CEO & Director Comp: $1.71MMs. Elizabeth L. Hougen M.A. (Age 62)M.B.A., M.S., Executive VP of Finance & CFO Comp: $1.02MMs. Onaiza Cadoret-Manier M.A. (Age 59)M.B.A., M.S., Executive VP and Chief Global Product Strategy & Operations Officer Comp: $930.82kMs. B. Lynne Parshall Esq. (Age 70)J.D., Senior Strategic Advisor & Director Comp: $334.64kDr. Richard S. Geary Ph.D. (Age 66)Executive VP & Chief Development Officer Comp: $946.26kMr. Joseph T. Baroldi M.A. (Age 45)M.B.A., M.S., Executive VP & Chief Business Officer Comp: $815.87kMr. Darren GonzalesChief Accounting Officer & Senior VPDr. C. Frank Bennett BSc (Age 67)Ph.D., Executive VP & Chief Scientific Officer Comp: $651.64kMr. D. Wade Walke Ph.D.Senior Vice President of Investor RelationsMr. Patrick R. O'Neil Esq. (Age 50)Executive VP, Chief Legal Officer, General Counsel & Corporate Secretary Comp: $815.69kMore ExecutivesKey CompetitorsMadrigal PharmaceuticalsNASDAQ:MDGLAlkermesNASDAQ:ALKSAmicus TherapeuticsNASDAQ:FOLDGeronNASDAQ:GERNUnited TherapeuticsNASDAQ:UTHRView All CompetitorsInsiders & InstitutionsNomura Holdings Inc.Sold 26,825 shares on 3/27/2024Ownership: 0.336%Vanguard Group Inc.Sold 298,544 shares on 3/11/2024Ownership: 9.745%Wellington Management Group LLPBought 2,856,353 shares on 3/5/2024Ownership: 3.168%Goldman Sachs Group Inc.Bought 30,000 shares on 3/1/2024Ownership: 0.000%Brett P MoniaSold 387 sharesTotal: $17,217.63 ($44.49/share)View All Insider TransactionsView All Institutional Transactions IONS Stock Analysis - Frequently Asked Questions Should I buy or sell Ionis Pharmaceuticals stock right now? 12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ionis Pharmaceuticals in the last year. There are currently 1 sell rating, 3 hold ratings, 7 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" IONS shares. View IONS analyst ratings or view top-rated stocks. What is Ionis Pharmaceuticals' stock price target for 2024? 12 Wall Street research analysts have issued 1-year price objectives for Ionis Pharmaceuticals' stock. Their IONS share price targets range from $28.00 to $72.00. On average, they predict the company's stock price to reach $55.67 in the next year. This suggests a possible upside of 28.4% from the stock's current price. View analysts price targets for IONS or view top-rated stocks among Wall Street analysts. How have IONS shares performed in 2024? Ionis Pharmaceuticals' stock was trading at $50.59 at the start of the year. Since then, IONS stock has decreased by 14.3% and is now trading at $43.35. View the best growth stocks for 2024 here. Are investors shorting Ionis Pharmaceuticals? Ionis Pharmaceuticals saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 9,670,000 shares, an increase of 6.1% from the February 29th total of 9,110,000 shares. Based on an average trading volume of 1,190,000 shares, the days-to-cover ratio is currently 8.1 days. Approximately 7.2% of the shares of the company are short sold. View Ionis Pharmaceuticals' Short Interest. When is Ionis Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024. View our IONS earnings forecast. How were Ionis Pharmaceuticals' earnings last quarter? Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) announced its quarterly earnings results on Wednesday, February, 21st. The company reported ($0.06) EPS for the quarter, beating analysts' consensus estimates of ($0.78) by $0.72. The business had revenue of $325 million for the quarter, compared to the consensus estimate of $176.01 million. Ionis Pharmaceuticals had a negative net margin of 46.32% and a negative trailing twelve-month return on equity of 90.29%. Ionis Pharmaceuticals's revenue for the quarter was up 113.8% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.37) earnings per share. What ETFs hold Ionis Pharmaceuticals' stock? ETFs with the largest weight of Ionis Pharmaceuticals (NASDAQ:IONS) stock in their portfolio include ARK Genomic Revolution ETF (ARKG), Morningstar US Small Growth (MSGR), First Trust NYSE Arca Biotechnology Index Fund (FBT), Horizon Kinetics Medical ETF (MEDX), Franklin Genomic Advancements ETF (HELX), Virtus LifeSci Biotech Products ETF (BBP), Principal Healthcare Innovators ETF (BTEC) and VanEck Morningstar SMID Moat ETF (SMOT). What guidance has Ionis Pharmaceuticals issued on next quarter's earnings? Ionis Pharmaceuticals updated its FY 2024 earnings guidance on Wednesday, February, 21st. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $575.0 million-, compared to the consensus revenue estimate of $636.4 million. What other stocks do shareholders of Ionis Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Ionis Pharmaceuticals investors own include Xtrackers California Municipal Bond ETF (CA), Micron Technology (MU), NVIDIA (NVDA), Gilead Sciences (GILD), Alibaba Group (BABA), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), BlackRock (BLK), Skyworks Solutions (SWKS) and Advanced Micro Devices (AMD). Who are Ionis Pharmaceuticals' major shareholders? Ionis Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (9.90%), Vanguard Group Inc. (9.75%), Bellevue Group AG (6.07%), Clearbridge Investments LLC (3.28%), Wellington Management Group LLP (3.17%) and Price T Rowe Associates Inc. MD (2.97%). Insiders that own company stock include Allene M Diaz, B Lynne Parshall, Brett P Monia, Brian Birchler, C Frank Bennett, Elizabeth L Hougen, Eric Swayze, Eugene Schneider, Frederick T Muto, Joseph Klein III, Onaiza Cadoret-Manier, Patrick R O'neil and Spencer R Berthelsen. View institutional ownership trends. How do I buy shares of Ionis Pharmaceuticals? Shares of IONS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:IONS) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI healthcare stock poised for 36,996% growth?Behind the MarketsBill Gates is all about this tiny $2 stockTimothy Sykes Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ionis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.